South Korea Pharma Report
By the end of 2017, the worldwide demand for active pharmaceutical ingredients (APIs) is estimated to reach $92 billion,12.10.2017
South Korea : Korea: Can High R&D Spending Lead To Commercial Success?
Local flagship company Boryung has found success with its newly developed angiotension receptor blocker (ARB) Kanarb. Nine molecules currently exist worldwide in this category of antihypertensives, and Kanarb is currently ranked eighth. “Boryung is the only domestic company that has …view more
Medytox is the most valuable pharmaceutical business in Korea, with a highly successful botulinum toxin product on the market, and can only grow further when they finish development of their second generation botulinum toxin product that will be commercialized globally …